---
schema_version: "secwatch.filing_event.v1"
accession: "0001999480-26-000001"
form_type: "8-K"
ticker: "ANRO"
cik: "0001999480"
company_name: "Alto Neuroscience, Inc."
filed_at: "2026-03-16T23:59:59+00:00"
generated_at: "2026-05-15T11:58:46.086024+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Alto Neuroscience reports FY2025 net loss $63.2M; cash $177M; ALTO-207 Phase 2b on track for 1H 2026

## Summary
- Cash, cash equivalents & restricted cash $177M as of Dec 31, 2025; runway into 2028 covers four key readouts.
- Net loss of $63.2M for FY2025 vs $61.4M in FY2024; R&D expenses $45.6M, G&A $20.7M.
- Acquired ALTO-207 (pramipexole/ondansetron) for TRD; Lancet-published PAX-D study showed Cohen's d=0.87 effect size.
- ALTO-207 Phase 2b trial expected to start 1H 2026, topline data 2H 2027; $50M PIPE completed in October 2025.
- ALTO-101 granted FDA Fast Track for CIAS; Phase 2 POC topline data expected around end of Q1 2026.

## SEC filing metadata
- accession: 0001999480-26-000001
- form_type: 8-K
- ticker: ANRO
- cik: 0001999480
- company_name: Alto Neuroscience, Inc.
- filed_at: 2026-03-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1999480/000199948026000001/0001999480-26-000001-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1999480/000199948026000001/alto-20260316.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001999480-26-000001
- JSON: https://secwatch.observer/filing/0001999480-26-000001.json
- Plain text: https://secwatch.observer/filing/0001999480-26-000001.txt

## Key facts
- Earnings Releases
  Alto Neuroscience, Inc. reported financial results for full year ended December 31, 2025.
  - Period: full year ended December 31, 2025
  - Result: reported results
  source text: On March 16, 2026, Alto Neuroscience, Inc. (the “Company”) reported financial results for the fiscal year ended December 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1999480/000199948026000001/0001999480-26-000001-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.